APOE expression and secretion are modulated by mitochondrial dysfunction
Meghan E. Wynne, Oluwaseun Ogunbona, Alicia R. Lane, Avanti Gokhale, Stephanie A. Zlatic, Chongchong Xu, Zhexing Wen, Duc M. Duong, Sruti Rayaprolu, Anna Ivanova, Eric A. Ortlund, Eric B. Dammer, Nicholas T. Seyfried, Blaine R. Roberts, Amanda Crocker, Vinit Shanbhag, Michael J. Petris, Nanami Senoo, Selvaraju Kandasamy, Steven M. Claypool, Antoni Barrientos, Aliza P. Wingo, Thomas S. Wingo, Srikant Rangaraju, Allan I. Levey, Erica Werner, Victor Faúndez
Abstract
Mitochondria influence cellular function through both cell-autonomous and non-cell autonomous mechanisms, such as production of paracrine and endocrine factors. Here, we demonstrate that mitochondrial regulation of the secretome is more extensive than previously appreciated, as both genetic and pharmacological disruption of the electron transport chain caused upregulation of the Alzheimer's disease risk factor apolipoprotein E (APOE) and other secretome components. Indirect disruption of the electron transport chain by gene editing of SLC25A mitochondrial membrane transporters as well as direct genetic and pharmacological disruption of either complexes I, III, or the copper-containing complex IV of the electron transport chain elicited upregulation of APOE transcript, protein, and secretion, up to 49-fold. These APOE phenotypes were robustly expressed in diverse cell types and iPSC-derived human astrocytes as part of an inflammatory gene expression program. Moreover, age- and genotype-dependent decline in brain levels of respiratory complex I preceded an increase in APOE in the 5xFAD mouse model. We propose that mitochondria act as novel upstream regulators of APOE-dependent cellular processes in health and disease.